Eli Lilly (NYSE: LLY) Stock Analysis: Morgan Stanley Raises Price Target as Shares Gain

• Morgan Stanley raised its price target for Eli Lilly (NYSE: LLY) to $1,430 from $1,419 while maintaining an Overweight rating.

• The firm’s new target represented potential upside of approximately 20.8% from an intraday share price of around $1,184.

• Separate analyses from 24/7 Wall St. and a Seeking Alpha contributor also presented bullish long-term views, although these are independent forecasts rather than analyst-consensus targets.

Eli Lilly (NYSE: LLY) develops medicines for several conditions, including diabetes, obesity, cancer, immunological disorders, and neurological diseases. Morgan Stanley raised its price target for Eli Lilly to $1,430 from $1,419 and maintained an Overweight rating on the stock.

With shares trading at approximately $1,184 during the October 7 session, Morgan Stanley’s new target implied potential upside of about 20.8%. The firm adjusted its biopharmaceutical models ahead of third-quarter earnings, citing prescription trends and other developments during the quarter. A price target is an analyst’s estimate and does not guarantee future performance.

Other published forecasts also see potential upside for Eli Lilly, although their estimates differ. 24/7 Wall St. published its own 12-month target of $1,359.12. Compared with the $1,142.85 share price used in that analysis, the target represented potential upside of approximately 18.92%. This was the publication’s proprietary forecast rather than the average target from Wall Street analysts.

A separate Seeking Alpha contributor maintained a Strong Buy rating on Eli Lilly. The author described the pharmaceutical company as a potential diversification holding for portfolios with substantial exposure to artificial-intelligence stocks and expressed confidence that Eli Lilly could outperform the S&P 500 over the long term. These statements represent the author’s opinion rather than a company forecast or broad analyst consensus.

The Seeking Alpha analysis estimated that Eli Lilly traded at approximately 24 times projected fiscal 2027 earnings. This means investors were paying about $24 for every $1 of profit expected that year. The author described this as a premium valuation but did not consider the stock excessively expensive relative to its growth prospects.

During the October 7 trading session, Eli Lilly shares traded at approximately $1,181.77, up $24.28, or 2.10%, at the quoted time. The stock had traded between approximately $1,166 and $1,187 during the session, compared with a 52-week range of $783.85 to $1,292.65. Its market capitalization was approximately $1.1 trillion. Because these were intraday figures, the share price, percentage change, volume, and market capitalization continued to fluctuate throughout the session.